Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-121 first-line metastatic non-small cell lung cancer study
jRCT2061230073Phase 3Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Zimberelimab + Domvanalimab + Chemotherapy, Pembrolizumab + Chemotherapy and Zimberelimab + Chemotherapy (3 arms). Primary endpoints: Overall Survival in participants with PD-L1 expression >=1% tumor cells and Overall Survival in all randomized participants. Started Jan 2024; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061230073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230073.